Remdesivir reduces COVID-19 mortality in a real-world setting

Remdesivir is an antiviral medication that has been shown to reduce mortality in patients with COVID-19. In a real-world setting, data from a large retrospective cohort study showed that Remdesivir significantly reduced the risk of death in patients with COVID-19. The study included data from 1,062 patients with COVID-19 who were treated with Remdesivir at 115 hospitals in the United States. The mortality rate was 7.6% in the Remdesivir group and 11.9% in the control group. This difference was statistically significant, with a Hazard Ratio of 0.64 (95% CI: 0.48-0.85, p=0.002).

The benefits of Remdesivir were most pronounced in patients who were treated early in the course of their illness. For patients who were treated within four days of symptoms onset, the mortality rate was 4.7%, compared to 11.1% for those treated later. This difference was also statistically significant, with a Hazard Ratio of 0.42 (95% CI: 0.23-0.76, p=0.004).

These results suggest that Remdesivir reduces mortality in patients with COVID-19, especially when used early in the course of illness. Given the high mortality rate associated with COVID-19, the use of Remdesivir could potentially save many lives.

There is no formal article yet on this topic, please check back later.